Allarity Therapeutics Inc (ALLR) — 13F Filings Explorer (Q2 2026)

ALLR ranks #8396 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ALLR is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

20 institutions disclose a position in ALLR, but none treat it as a major bet — even Renaissance Technologies LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

State Street has added to its ALLR position for two straight quarters, increasing it by $28.9K to reach $177.5K today.

XTX Topco Ltd has trimmed its ALLR position for two straight quarters, cutting it by $9.4K while still holding $26.9K.

ALLR reported a net loss of $11.2M in its latest fiscal year.

• Not yet profitable — net loss of $11.2M in the latest fiscal year
• Net income improved year over year, from -$24.5M to -$11.2M
• Operating cash flow was negative, using $14.8M in cash
• Current ratio of 2.13x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.86x equity — within a conventional range